Etiopathogenesis of Otosclerosis and Its Management

INTRODUCTION

EPIDEMIOLOGY

ETIOPATHOGENESIS

1. GENETIC FACTORS

• Autosomal dominant inheritance with incomplete penetrance (~25–40%). (Harrison's, p. 1024)
• Multiple susceptibility loci (OTSC1–OTSC10) have been mapped on chromosomes 15q25-q26, 7q34-q36, 6p21-22, 16q21-23, 3q22-24, and others.
• TGFB1 (Transforming Growth Factor Beta-1) gene mutations on chromosome 19q13 are strongly associated — TGF-β1 is a key regulator of bone remodeling.
• RELN (Reelin gene, chromosome 7q22) polymorphisms affect otocyte differentiation.
• Association with osteogenesis imperfecta (Type I collagen gene mutation — COL1A1/COL1A2), highlighting the shared bone dyscrasia mechanism. (Harrison's, p. 1024)
• Despite autosomal dominant pattern, only 25–40% penetrance means many gene carriers never develop clinical disease.

2. VIRAL ETIOLOGY — MEASLES VIRUS HYPOTHESIS

• Parainfluenza virus type-1 (closely related to measles) has been implicated.
• Arnold (1996) and McKenna (1986) demonstrated measles virus RNA (by RT-PCR) and antigens in otosclerotic foci, suggesting persistent measles virus infection of osteoblasts as a trigger for aberrant remodeling.
• The measles virus nucleocapsid protein binds to receptor activator of NF-κB (RANK), potentially disrupting osteoclast-osteoblast coupling.
• The decline in otosclerosis incidence following widespread measles vaccination supports this association.
• Circulating anti-measles antibodies are elevated in otosclerosis patients.
• However, the viral hypothesis remains controversial, as several studies failed to replicate these findings.

3. HORMONAL FACTORS

• Estrogen accelerates otosclerosis progression — explains:
  • Female preponderance in clinical disease
  • Acceleration during pregnancy (estrogen surge), often when hearing loss is first noticed (Harrison's, p. 1024)
  • Worsening during menstruation and oral contraceptive use
• Estrogen receptors are present on osteoblasts in the otic capsule.
• Estrogen upregulates TGF-β1 and promotes local bone remodeling.

4. IMMUNOLOGICAL FACTORS

• Elevated levels of IgG, IgA, and IgM autoantibodies against type II collagen (a major component of the otic capsule endochondral layer).
• Activated macrophages and mast cells in otosclerotic foci release cytokines (IL-1, TNF-α, TGF-β).
• Complement activation and immune complex deposition within the otic capsule.
• Immune-mediated inflammation triggers aberrant bone resorption by activated osteoclasts.

5. PATHOLOGICAL BASIS — THE BONE REMODELING DYSREGULATION

Key Biochemical Events:

• RANKL/OPG axis dysregulation: Elevated RANKL and reduced Osteoprotegerin (OPG) → enhanced osteoclast activation.
• Matrix metalloproteinases (MMPs): MMP-2 and MMP-9 are upregulated → degradation of type I and II collagen.
• TGF-β1 overexpression → paradoxical stimulation of abnormal bone formation after resorption.
• Vascular endothelial growth factor (VEGF) overexpression → hypervascularization of foci.
• Elevated alkaline phosphatase locally reflects increased osteoblastic activity.

6. HISTOPATHOLOGY

Two Phases:

Sites of Predilection:

1. Fissula ante fenestram (anterior to oval window) — the most common site (~80%)
2. Posterior oval window margin
3. Round window niche (round window otosclerosis — rare but causes worse hearing loss)
4. Cochlear otosclerosis — perilabyrinthine spread causing sensorineural or mixed hearing loss

Spread:

• Foci originate in the endochondral layer of the otic capsule
• Extend to involve the stapediovestibular joint → annular ligament → stapes fixation → conductive hearing loss
• Further extension into the cochlea → cochlear otosclerosis → mixed/SNHL

7. MECHANISM OF HEARING LOSS

CLINICAL FEATURES

• Progressive bilateral conductive hearing loss — insidious onset in late teens to forties.
• Paracusis Willisii — paradoxical improvement of hearing in noisy environments (pathognomonic but not specific).
• Tinnitus — low-frequency, continuous.
• Negative Rinne test bilaterally; Weber lateralizes to worse ear.
• Schwartze sign (Flamingo pink blush) — reddish/pinkish hue seen through the tympanic membrane; indicates active vascular otospongiosis over the promontory.
• Normal tympanic membrane and external ear canal.
• Absent stapedial reflexes on tympanometry.

AUDIOLOGICAL AND RADIOLOGICAL FINDINGS

MANAGEMENT

A. MEDICAL MANAGEMENT

1. Sodium Fluoride (NaF)

• Drug of choice for medical management (Harrison's, p. 1024)
• Mechanism: Fluoride ions replace hydroxyl groups in hydroxyapatite → forms fluorapatite, which is more resistant to enzymatic dissolution; also inhibits enzymes (lysosomal proteases) released by osteoclasts.
• Dose: 25 mg TDS (75 mg/day) for at least 2 years
• Monitoring: Serum fluoride levels, urine fluoride, X-rays for fluorosis
• Indications: Active otosclerosis (Schwartze sign positive), cochlear otosclerosis, SNHL component
• Side effects: Fluorosis (mottled teeth, skeletal changes), GI upset, renal toxicity (long-term)
• Reduces progression, particularly of cochlear otosclerosis

2. Bisphosphonates

• Etidronate, risedronate — second-line agents
• Inhibit osteoclast function → reduce bone resorption in active foci
• Adjunct to sodium fluoride in cochlear otosclerosis

3. Calcium and Vitamin D Supplementation

• Prescribed alongside fluoride to prevent systemic hypocalcemia and secondary hyperparathyroidism

4. Estrogen Modulation

• Avoid exogenous estrogens (oral contraceptive pills) in women with otosclerosis, especially during active phase
• Low-dose progesterone-only contraception preferred

5. Hearing Aid

• Effective, especially for bilateral disease, elderly patients, poor surgical candidates, cochlear involvement
• Body-worn/behind-the-ear aids preferred
• The only non-surgical rehabilitation tool

B. SURGICAL MANAGEMENT

Historical Evolution:

1. STAPEDECTOMY (Total / Partial)

• The entire stapes superstructure and footplate are removed.
• The oval window is sealed with fat, vein graft, or perichondrium.
• A piston prosthesis (Teflon, stainless steel, titanium) is placed from the long process of incus into the graft.

• Only part of the footplate removed; remainder sealed.
• Less favored than stapedotomy.

2. STAPEDOTOMY (Small Fenestra Technique) — Current Gold Standard

• A 0.6–0.8 mm fenestra (small hole) is made in the stapes footplate using a:
  • Micro-drill (manual)
  • CO₂ laser (KTP laser — preferred; avoids mechanical trauma)
  • Erbium:YAG laser
• A Teflon piston prosthesis (0.4–0.6 mm diameter, 4–4.5 mm length) is inserted from the long process of incus into the fenestra.
• Advantages over total stapedectomy:
  • Lower incidence of sensorineural hearing loss ("dead ear")
  • Less perilymph aspiration risk
  • Better high-frequency results
  • Faster recovery

SURGICAL STEPS (Stapedotomy):

1. Endaural or postauricular approach under local/general anesthesia
2. Elevation of tympanomeatal flap — exposure of middle ear
3. Confirmation of stapes fixation (Gelle's test intraoperatively)
4. Division of stapedial tendon
5. Separation of incudostapedial joint
6. Fracture/removal of stapes crura
7. Laser fenestration of footplate
8. Sizing and placement of piston prosthesis over long process of incus
9. Sealing with blood clot/fat plug around the piston
10. Replacement of tympanomeatal flap; packing

PROSTHESIS TYPES:

CONTRAINDICATIONS TO SURGERY:

COMPLICATIONS OF SURGERY:

RESULTS OF SURGERY:

• Success rate: ~90–95% achieve closure of air-bone gap to within 10 dB
• Dead ear rate: <1–2% with modern stapedotomy
• Long-term results are stable in most patients; may deteriorate if cochlear otosclerosis progresses

C. REHABILITATION

• Bone-anchored hearing aids (BAHA) — for patients who cannot undergo or failed surgery
• Cochlear implantation — for end-stage cochlear otosclerosis with profound SNHL; results are fair but can be technically challenging due to obliterative cochlear lesions

SUMMARY TABLE

CONCLUSION

References:

• Harrison's Principles of Internal Medicine, 21st Edition, p. 1024
• Dhingra PL — Diseases of Ear, Nose and Throat, 7th Edition
• Scott-Brown's Otorhinolaryngology Head & Neck Surgery, 8th Edition
• Cummings Otolaryngology — Head and Neck Surgery, 7th Edition
• Shea JJ (1958) — "Fenestration of the Oval Window", Ann Otol Rhinol Laryngol
• McKenna MJ et al. — Measles virus RNA and otosclerosis, Am J Otol, 1986

1. Etiopathogenesis Flowchart

2. HRCT Temporal Bone — Fenestral Otosclerosis

• 🟢 Green arrows — Hypodense foci (decreased bone density) at the fissula ante fenestram, immediately anterior to the oval window — the most common site (~80%)
• 🔵 Blue arrows — Thickening of the stapes footplate due to otosclerotic fixation
• Note the surrounding mastoid air cells, semicircular canals, and internal auditory canal for anatomical orientation
• Pathologically, these hypodensities represent replacement of dense otic capsule cortical bone by vascular spongy otospongiotic bone

3. Intraoperative Endoscopic Views — Stapedotomy

4. Surgical Management Flowchart

• Active otospongiosis (Schwartze sign positive) → sodium fluoride + bisphosphonates
• Conductive HL → surgical candidacy assessment → stapedotomy (gold standard) with sequential operative steps
• Poor surgical candidates → hearing aid / BAHA
• End-stage cochlear otosclerosis with profound SNHL → cochlear implantation

Quick Visual Summary of Key Concepts